FOLH1 and prostate cancer: CAFs express fibroblast activation protein (FAP) that can be targeted with 68Ga-radiolabeled quinoline-based inhibitors of FAP (FAPI) [169,170]. 68Ga-FAPI has shown promise in detecting metastasis of various cancer types, including PSMA-negative prostate cancer metastases [169,170].